Vanguard Global Advisers
AQST icon

Vanguard Global Advisers’s Aquestive Therapeutics AQST Stock Holding History

Vanguard Global Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Hold
38,488
– – ﹤0.01% 2587
2026
Q1 		$160K Buy
+38,488
New +$156K ﹤0.01% 2542

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vanguard Global Advisers's AQST Position: Q2 2026 in Review

Vanguard Global Advisers held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 38,488 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Vanguard Global Advisers first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Vanguard Global Advisers held 38,488 shares of Aquestive Therapeutics worth $160K as of Q2 2026.
  • Vanguard Global Advisers left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2587 holding.
  • Vanguard Global Advisers first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 183 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.